Proteins - especially monoclonal antibodies (MABs) - have become increasingly important in pharmaceutical work. However, there are some important differences between conventional, chemically-synthesized drugs and proteins. Because of the complex and weak structure of proteins, even a slight change in conditions, such as pH value, temperature, or mechanical stress, may lead to aggregation and a loss of activity or stability.
The rational development of AF4 methods for the investigation of VLP is illustrated.